- 3 hours ago
- 12 min read
Key Takeaways
China leads on CAR-T access and price: With multiple NMPA-approved CAR-T products and hospitals like GoBroad Healthcare Group offering CAR-T from roughly $30,000–$80,000 for the drug component alone (packages scaling up with hospitalization and monitoring), China currently offers the broadest combination of approved lymphoma cell therapies at the lowest price point in Asia.
South Korea offers top-tier infrastructure at a premium: Samsung Medical Center runs Korea's first dedicated CAR-T Cell Therapy Center and has held the country's No. 1 hospital quality ranking for 16 consecutive years, with cancer treatment costs generally in the $15,000–$60,000 range (excluding CAR-T-specific pricing, which runs higher).
India and Singapore excel at accessible, high-volume hematology care: Hospitals like Apollo Cancer Centre (India) and National Cancer Centre Singapore have deep case volume and strong international patient infrastructure, though commercial CAR-T access is more limited than in China or Korea.
No single country wins on everything: The right choice depends on your lymphoma subtype, whether you need CAR-T specifically, your budget, and how much travel distance and language difference you can manage.
ChinaCureLink can help international patients navigate China’s treatment options by connecting them with leading hospitals and specialists, helping identify appropriate treatment programs, coordinate medical records and consultations, and support the process of exploring care in China.
Why Patients Are Looking to Asia for Lymphoma Treatment
Lymphoma treatment costs in the US and Western Europe have climbed sharply, particularly for CAR-T cell therapy — commercial products like Yescarta and Kymriah list at $373,000–$475,000 before hospitalization, pushing all-in US treatment costs toward $500,000–$800,000.
Asia has responded with two distinct value propositions. China built an independent CAR-T manufacturing and regulatory pathway, bringing multiple approved lymphoma cell therapies to market at a fraction of Western pricing. Meanwhile, established medical hubs — South Korea, Singapore, India, Thailand, and Malaysia — have spent two decades building world-class oncology infrastructure specifically to serve international patients, with strong outcomes data, JCI accreditation, and multilingual support.
The result: patients now have real, clinically credible options across the region — not just a single "cheap" destination, but a genuine spectrum of infrastructure, price, and specialization to match different needs.
How These Hospitals Were Chosen
Hospitals in this guide were selected based on:
National or regional specialty reputation rankings (e.g., Fudan University Hospital Management Institute for China, Newsweek World's Best Hospitals for regional comparisons)
Documented hematology/lymphoma case volume and CAR-T program authorization where applicable
International accreditation (JCI, NABH) and established international patient departments
Published clinical outcomes or institutional trial data, where available
A transparency note: exact case volumes, survival statistics, and international patient counts in this space often come from institutional or industry reporting rather than independently audited registries. Use this guide as a starting point for research and always confirm current details directly with the hospital.
The 5 Best Lymphoma Hospitals in Asia
If you only read one section of this guide, make it this one. These five hospitals combine deep hematology-specific expertise, credible CAR-T or advanced treatment infrastructure, and established international patient programs.
1. Lu Daopei Hematology Hospital — Beijing & Hebei, China
Lu Daopei is arguably the most specialized blood-cancer hospital in Asia — it treats only hematologic diseases (leukemia, lymphoma, myeloma, and rare blood disorders), rather than operating as a general cancer center with a hematology department bolted on.
Founder and legacy: Named after Dr. Lu Daopei, a pioneer of bone marrow transplantation in China and academician at the Chinese Academy of Engineering. The hospital group now operates multiple campuses (Beijing, Hebei/Yanda, and Shanghai), reported at roughly 300–490+ beds at the Beijing site depending on the specific campus and source, with dozens of Class 100 sterile laminar-flow rooms built for transplant and cell-therapy patients.
CAR-T track record: Lu Daopei has run one of the longest-running CAR-T clinical trial programs in China — over 1,100 patients had been treated through its CAR-T trials by 2021, with a reported complete remission rate around 90% in that program. It has also pioneered "CAR-T bridging to allogeneic stem cell transplant," a technique aimed at reducing relapse risk after CAR-T.
Transplant volume: One of the most active stem cell transplant centers globally, reportedly completing several hundred allogeneic transplants annually — high volume that tends to correlate with more refined post-transplant complication management.
International patient support: Multilingual care coordinators, personalized treatment planning, and support from initial diagnosis through post-treatment follow-up.
Best for: Patients with relapsed/refractory leukemia or lymphoma who specifically want a hospital where hematology is the entire focus, not one department among many — especially those considering CAR-T bridged to transplant for higher relapse risk cases.
2. Samsung Medical Center — Seoul, South Korea
South Korea's top-ranked hospital for 16 consecutive years in the national Service Quality Index, and home to Korea's first dedicated CAR-T Cell Therapy Center.
CAR-T program: Treats relapsed/refractory CD19-targeted B-cell lymphoma, BCMA-targeted multiple myeloma, and pediatric B-lymphoblastic leukemia, with inpatient beds reserved specifically for CAR-T patients to guarantee timely access and a dedicated CAR-T clinic for continuous pre-, during-, and post-treatment monitoring.
International credibility: Formal clinical partnership with MD Anderson Cancer Center and the first hospital globally to achieve HIMSS Stage 7 across all four digital health frameworks — a marker of advanced, well-integrated digital patient records and safety systems.
Outcomes: Reported 5-year survival rates for stomach, lung, and liver cancer exceeding both Korean national figures and US SEER benchmarks.
Best for: Patients who want elite, highly structured infrastructure and are less cost-sensitive than the China-based options — particularly those who value a long, consistent quality track record over pure price.
3. National Cancer Centre Singapore (NCCS)
A cancer-only referral hospital (not a general hospital with an oncology wing), giving it a tightly focused hematology-oncology team with substantial published research output.
Research depth: Co-author of multicenter Asian lymphoma outcomes studies alongside Samsung Medical Center and Sun Yat-sen University Cancer Center, covering aggressive subtypes like peripheral T-cell lymphoma and NK/T-cell lymphoma — cancers that are more common in Asian populations and less commonly studied in Western centers.
Regional collaboration: Active participant in multi-country clinical trials across Singapore, Malaysia, and South Korea, reflecting strong ties into the region's broader research network.
Best for: Patients with rarer lymphoma subtypes (especially T-cell or NK/T-cell lymphomas) who want a center with specific published experience in exactly their diagnosis, not just aggressive B-cell lymphoma.
4. Apollo Cancer Centre — India (Multi-City Network)
India's largest private oncology network, offering CAR-T within its haemato-oncology program for relapsed/refractory blood cancers.
Scale: Serves patients from over 120 countries, with thousands of bone marrow transplants performed across the Apollo network — one of the highest-volume hematology infrastructures in the region.
Accreditation and support: NABH accreditation, dedicated transplant ICUs, international patient lounges, visa assistance, airport transfers, and coordinated oncology consultations built specifically for overseas patients.
Best for: Patients seeking a strong balance of cost, volume, and established international infrastructure — particularly those for whom China's CAR-T pricing is attractive but who want a broader hospital network and English-first coordination.
5. Bumrungrad International Hospital — Bangkok, Thailand
One of the highest-volume international patient hospitals in the world, JCI-accredited since 1997, and built from the ground up to serve overseas patients.
Scale and reach: Treats over 520,000 international patients annually, with support across more than 70 languages — a level of multilingual infrastructure few hospitals globally can match.
Oncology and hematology capability: Broad cancer and blood-disorder treatment infrastructure integrated with Bumrungrad's larger multi-specialty hospital system, useful for patients with lymphoma alongside other complex health conditions.
Best for: Patients who want extremely mature international-patient logistics — interpreters, travel coordination, insurance direct-billing — and may have language needs beyond English, or who are weighing lymphoma treatment alongside other health concerns best handled at a full-service hospital.
More Top Lymphoma Hospitals in Asia by Country
Beyond the top 5 above, these hospitals are also worth researching depending on your specific case:
China
GoBroad Healthcare Group (Beijing & Shanghai) — A private hospital network built specifically around hematologic malignancies and cell therapy, offering CAR-T and stem cell transplantation with structured multidisciplinary teams. Best for patients prioritizing CAR-T-specific infrastructure with English-language coordination.
Ruijin Hospital (Shanghai) — Deep hematology research pedigree; its team has reported strong response rates in novel CAR-T trials for hematologic cancers.
Peking Union Medical College Hospital (PUMCH) — China's top-ranked comprehensive hospital, well-suited to complex or atypical lymphoma presentations with its Cellular Immunotherapy Center.
South Korea
Severance Hospital (Yonsei Cancer Hospital, Seoul) — Korea's first dedicated cancer hospital, with 13 specialized cancer centers and a strong interdisciplinary oncology team.
Singapore
Icon Cancer Centre (Singapore) — A dedicated cancer-only network across multiple locations, with hematology and bone marrow transplant capability.
India
Kokilaben Hospital (Mumbai) — A structured bone marrow transplant and haemato-oncology unit for complex leukemia and lymphoma, serving patients from 70+ countries with a full international patient desk
Fortis Healthcare — CAR-T offered in select cases within a broader haemato-oncology program, with interpreter services and visa letter support.
Malaysia
Sunway Medical Centre (Kuala Lumpur) — JCI-accredited, recognized in Newsweek's Malaysia hospital rankings, with strong radiotherapy infrastructure (TomoTherapy, Gamma Knife) alongside hematology services.
Cost Comparison: Lymphoma Treatment Across Asia
Beyond CAR-T specifically, general oncology treatment costs (chemotherapy, radiotherapy, standard hematology care) vary by country:
Country | Typical Oncology Cost Range (USD) | Notable Strength |
China | $8,000–$35,000 for many procedures; CAR-T as above | Lowest-cost CAR-T access with multiple approved products |
South Korea | $15,000–$60,000 | Top-ranked infrastructure, strong 5-year survival data vs. national/US benchmarks |
India | Generally the most cost-competitive for standard hematology/BMT care | High volume, broad international patient networks |
Thailand | Competitive with India for standard oncology care | Extremely high international patient volume, JCI since 1997 |
Malaysia | Moderate | Strong radiotherapy technology, JCI accreditation |
Approved CAR-T vs. Clinical Trial CAR-T
One of the most important distinctions patients should understand is the difference between an approved CAR-T treatment and an investigational CAR-T therapy.
An approved product has passed the relevant regulatory review for specific indications. A clinical-trial CAR-T may involve:
A new target
A new CAR design
A dual-target construct
An allogeneic or donor-derived product
A new manufacturing method
A new cancer indication
Clinical trials can be important for patients who have exhausted standard options, but participation requires meeting specific eligibility criteria. A hospital conducting a large number of CAR-T trials does not mean that every patient will qualify for one.
Why CAR-T Hospital Experience Matters
CAR-T treatment is not simply an infusion.
The treatment pathway can include:
Medical-record and eligibility assessment
Target-antigen testing
T-cell collection through leukapheresis
CAR-T cell manufacturing
Bridging therapy when necessary
Lymphodepleting chemotherapy
CAR-T infusion
Monitoring for cytokine release syndrome
Monitoring for ICANS and other neurological complications
Infection prevention and treatment
Disease-response assessment
Long-term follow-up
The patient may therefore spend several weeks or longer in close contact with the treating center. This is why hospital infrastructure matters.
Should You Travel to Another Country for CAR-T Before Getting a Second Opinion?
Usually, it is better to have the case reviewed before traveling. CAR-T treatment involves significant preparation, and international travel adds additional complexity.
A remote specialist review can help determine:
Whether CAR-T may be appropriate
Which target may be relevant
Whether an approved product is available
Whether a clinical trial may be appropriate
Whether another treatment should be given first
Whether transplantation should be considered
Which hospital is most relevant to the case
Only after these questions are addressed does it make sense to seriously consider international travel.
How ChinaCureLink Can Help Compare CAR-T Options
For an international patient, finding a CAR-T hospital is not simply a matter of choosing the hospital with the biggest name. The patient needs to identify the center whose specific expertise matches the disease and treatment history.
ChinaCureLink provides oncology second opinions and hospital matching in China, including coordination of medical records, specialist consultations, hospital selection, and international treatment logistics.
For patients specifically researching CAR-T, ChinaCureLink's CAR-T treatment guide for international patients explains CAR-T options, eligibility considerations, and the treatment landscape in China.
Its step-by-step guide to getting CAR-T in China explains the practical process from medical-record submission through specialist evaluation and treatment coordination.
Get a CAR-T Second Opinion Before Choosing a Hospital
If you are comparing CAR-T hospitals around the world, you do not necessarily need to choose one immediately.
A more useful first step is to have your case reviewed by specialists who can determine which treatment centers are actually relevant to your disease.
Depending on the diagnosis and treatment history, the review can help determine which specialist center should be considered.
The specialist can discuss:
Whether CAR-T is appropriate
Which CAR-T target may be relevant
Whether an approved product or clinical trial may be appropriate
Whether additional testing is required
Whether bridging therapy may be needed
Whether transplantation should be considered
What alternative treatment options remain
For suitable cases, ChinaCureLink can then coordinate an online consultation with the specialist to discuss the technical treatment details directly. The purpose is to help the patient understand which treatment option and which specialist center may be most appropriate before making an international treatment decision.
What Patients Say About ChinaCureLink & Medebound HEALTH
China CureLink operates under Medebound HEALTH — an internationally recognized healthcare navigation company incorporated in New York, with operations across North America and Asia-Pacific.
Rated 4.6 ⭐⭐⭐⭐⭐ at Trustpilot
Medebound HEALTH's online testimonials. Learn More
★★★★☆ Sarah Zhang · Canada· Jul 2024 · Verified “The interpreter during the video call was fantastic — super professional and answered all our questions clearly and quickly. The professor was also very patient and gave us detailed and honest guidance on our treatment options.” |
★★★★★ Andrew Goh · Singapore · Aug 2024 · Verified “My first contact with Medebound was over a year ago. Jason has always been responsive, even when I wasn't ready to proceed. When I finally did, the consultation was seamlessly arranged and the specialist was outstanding.” |
★★★★★ Daniel Wong · Singapore · Aug 2024 · Verified “I have dry eye and nothing seemed to be working, even with different medications. I heard about a medication from the U.S. that’s supposed to be really effective, but I didn’t want to try it without talking to a doctor first. MEDEBOUND connected me with a top ophthalmologist in the U.S. and it was so reassuring to get their expert advice.” |
★★★★☆ Pongsakorn · Thailand · Feb 2025 · Verified “Kiki at Medebound is amazing — so professional and helpful! They got my video consultation with an MD Anderson expert set up super fast, within just 5 working days. I am so grateful for their support.” |
Frequently Asked Questions
1. Which Asian country offers the cheapest CAR-T therapy for lymphoma?
China currently offers the lowest CAR-T pricing in Asia, with complete treatment packages commonly running $120,000–$180,000 USD, and some hospital drug-component quotes as low as $30,000–$80,000 — versus $500,000–$800,000+ for equivalent treatment in the US. Always confirm whether a quoted price is the full package or just one component (drug cost vs. hospitalization and monitoring).
2. How do I access lymphoma treatment as an international patient in Asia?
Start with a remote case review at a hospital with an established international patient department — such as GoBroad or Ruijin in China, Samsung Medical Center in South Korea, or Apollo Cancer Centre in India. You'll typically need pathology confirmation of your lymphoma subtype, documented treatment history, and relevant biomarker testing. Once accepted, the hospital issues an invitation or confirmation letter used for your visa application.
3. What visa do I need for lymphoma treatment in Asia?
It depends on the country: China generally requires an S2 visa (or S1 for longer stays), South Korea uses a dedicated medical visa pathway through registered hospitals, India offers an e-Medical Visa, and Thailand has a Medical Treatment Visa (Category M) for longer courses. In every case, apply as soon as you receive your hospital's invitation letter and allow 4–6 weeks of processing buffer.
Can international patients receive CAR-T treatment?
Potentially, but eligibility depends on the hospital, treatment, regulatory requirements, disease status, and medical condition. A hospital offering CAR-T does not mean that every international patient will qualify.
Should I choose a CAR-T hospital based on its response rate?
No. Response rates from different studies cannot be compared directly without considering the patient population, cancer subtype, treatment line, CAR-T construct, eligibility criteria, and length of follow-up. A response rate reported in a clinical trial is not a prediction of an individual patient's outcome.
What is the best first step if I am considering CAR-T abroad?
Start with a specialist review of your medical records. The purpose is to determine whether CAR-T is potentially appropriate, which targets may be relevant, which hospitals have the most relevant experience, and whether traveling for treatment is medically worthwhile.
Final Thoughts
Asia now offers genuinely differentiated lymphoma treatment options — China's low-cost, multi-product CAR-T access; South Korea's elite, long-track-record infrastructure at Samsung Medical Center; India's high-volume, cost-competitive hematology networks; and Thailand's massive, multilingual international patient infrastructure. The right choice isn't about finding the single "best" country, but matching your specific lymphoma subtype, budget, and logistical needs to the center best equipped for your case.
If you're evaluating options, the responsible next step is a remote case review with a qualified hematology-oncology team, backed by your existing pathology and treatment records. For guidance comparing hospitals, eligibility, and logistics across countries, see our https://www.chinacurelink.com/post/cancer-treatment-in-china-a-complete-guide-for-southeast-asian-patients-2026
About ChinaCureLink
ChinaCureLink helps patients across the world access the best cancer treatment at China's top hospitals, without the delays, language barriers, and administrative confusion that typically come with seeking care abroad.
We connect patients directly with China's top cancer hospitals, ensuring that from the first case submission through to treatment and follow-up, every step is guided, translated, and coordinated by a team experienced in cross-border patient care.
ChinaCureLink is proudly affiliated with Medebound HEALTH — founded by US physicians, with over 10 years of experience and more than 3,000 patients served worldwide, Medebound HEALTH is recognized by Forbes and it is one of the most trusted patient cross-border concierge service company across North America and the Asia Pacific.
Disclaimer
This article is for informational purposes only and is not medical or financial advice. Treatment eligibility, protocols, and costs vary by individual case — confirm specifics with a coordinator and treating physician before making any decisions.
References
PMC / National Library of Medicine — Outcomes of patients with peripheral T-cell lymphoma in first complete remission: data from three tertiary Asian cancer centers
PMC / National Library of Medicine — A clinicohaematological prognostic model for nasal-type NK/T-cell lymphoma: A multicenter study
ClinicalTrials.gov — Study of Bortezomib and Panobinostat in Relapsed/Refractory Peripheral T-cell Lymphoma or NK/T-cell Lymphoma
Lu Daopei Hospital — CAR-T Therapy Center overview and clinical trial data
Comments